| Source: Oculis Holding AG
ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the purchase of ordinary shares by a member of the Company’s Board of Directors.
Attachments
ZUG, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic...
Read MorePRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative...
Read More